<scp>Ligand‐assisted imprinting‐probe‐labeling</scp> strategy reveals Siglec‐7 ‐ glycoprotein interactions

Li, Pei‐Jhen; Kawade, Sachin Kisan; Adak, Asok; Shen, Yu‐Ju; Fan, Chen-Yo; Hsieh, Yi-Hsun; Angata, Takashi; Chen, Yu‐Ju; Lin, Chun Cheng

doi:10.1002/jccs.202200127

Cited by 1 publication

(1 citation statement)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 26 ] To prepare azido‐functionalized glass slides, a zwitterion was included in a mixture of the thiolated PEG‐azide and short‐chain PEG spacer. [ 26, 27 ] This enables oriented and covalent immobilization through click conjugation between the remaining alkyne moieties specifically at the hinge region of the BsAbC and azides attached to the surfaces. However, conjugation through free alkynes at the C H 1 Fab region is also possible (Figure 4a).…”

Section: Resultsmentioning

confidence: 99%

Site‐selective heterodimerization of antibody fragments for bispecific antibody complexes enabled by divinylpyrimidine reagent

Kawade

Kuo

et al. 2023

J Chinese Chemical Soc

Self Cite

View full text Add to dashboard Cite

BackgroundBispecific Abs (BsAbs) are useful class of Ab‐based drugs but with difficulty to fabricate them.AimsCross‐linking two Abs by click chemistry.Materials & MethodsBis‐alkynylated divinylpyrimidine (DVP) was synthesized and incorporated into an Ab, which was then cross‐linked with azido‐modified Ab to produce BsAb.ResultsThe heterodimeric anti‐PD‐L1‐HER2 BsAbC was prepared by CuAAC and its formation was confirmed by SDS‐PAGE. BsAbC was purified by biotinylated HER2 antigen coated magnetic bead and was used to fabricate a microarray. In the microarray binding assay, the heterodimeric anti‐PD‐L1‐HER2 BsAbC showed binding activity with PD‐L1 and HER2 antigens.DiscussionThis study represents the first proof‐of‐concept that bis‐alkynylated DVP crosslinker reagent can be used for conjugating half‐antibody fragments site‐selectively by CuAAC. A preliminary characterization revealed that this reagent predominantly incorporates a bioorthogonal functional handle into the desired half‐antibody fragments with minor amounts of a re‐bridged full‐length antibody.ConclusionThis study highlights the utility of DVP crosslinker reagents and validates the use of these molecules for the rapid assembly of switchable complex antibody bioconjugates that enables the control of the intended function of fabricated BsAbC.

show abstract

Section: Resultsmentioning

confidence: 99%